---
title: "AI/ML SaMD Glossary & Acronym Decoder · AI SaMD Playbook"
url: https://ai-samd.com/glossary
description: "Searchable glossary of AI/SaMD regulatory terminology · FDA, EU AI Act, MDR, MHRA, IMDRF, GMLP, PCCP, and more."
lang: en
---

AI SaMD Playbook: https://ai-samd.com/

Talk to us →: https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session

Back to AI SaMD Playbook (https://ai-samd.com/)Reference · 41 terms

# Glossary & _acronym_ decoder

The vocabulary of AI medical devices, in one place. Hover any term in the wider site for a quick definition; come here for the full entry, the source, and the cross-links.

41 of 41

- ## 510(k)
  #510k
  Premarket Notification under section 510(k) of the FD&C Act
  FDA submission demonstrating that a device is substantially equivalent to a legally marketed predicate device.
  The most common pathway for Class II devices. AI/ML-specific recommendations apply (GMLP, transparency principles, PCCP for planned post-market modifications).
  FDA
  See also De NovoPMAPCCP
- ## AIaMD
  #aiamd
  Artificial Intelligence as a Medical Device
  MHRA's term for AI/ML-enabled medical-device software, the UK counterpart of FDA's AI/ML-DSF.
  A subset of SaMD where the medical purpose is achieved using AI/ML. Subject to UK MDR 2002 (post-Brexit) and the MHRA's evolving AIaMD framework.
  UK AI/ML
  See also SaMDMHRA
- ## Annex III
  #annex-iii
  AI Act Annex III, High-Risk Use Cases
  Standalone list of high-risk AI use cases (biometrics, employment, education, essential services, law enforcement, migration, justice, democracy).
  Distinct from the Art. 6(1) Annex I route used by medical-device AI. An Art. 6(3) derogation is available for narrow procedural / preparatory tasks unless the system performs profiling.
  EU AI/ML
  See also Article 6EU AI Act
- ## Article 6
  #article-6
  AI Act Article 6, Classification Rules for High-Risk AI
  Two routes to high-risk: (1) safety component of a product covered by Annex I harmonisation legislation requiring third-party conformity, or (2) listed in Annex III.
  Medical-device AI reaches high-risk via Art. 6(1) because the MDR is in Annex I and Class IIa+ devices require Notified Body assessment. Art. 6(3) provides a derogation for narrow procedural / preparatory tasks.
  EU AI/ML
  See also EU AI ActAnnex IIIMDR
- ## CE Mark
  #ce-mark
  Conformité Européenne marking
  Mark affixed to products that comply with applicable EU regulations, including the MDR/IVDR.
  For Class IIa+ medical devices the CE mark is accompanied by the four-digit identifier of the Notified Body that performed conformity assessment.
  EU
  See also Notified BodyMDR
- ## De Novo
  #de-novo
  De Novo Classification Request
  FDA pathway for novel low-to-moderate-risk devices for which no predicate exists; creates a new Class I or II classification.
  Used when general (and special) controls are sufficient to provide reasonable assurance of safety and effectiveness but no suitable 510(k) predicate exists. Successful De Novo grants become predicates for future 510(k)s.
  FDA
  See also 510(k)PMA
- ## Drift
  #drift
  Dataset / Concept Drift
  Degradation in model performance over time as the deployment data distribution diverges from the training distribution.
  Two flavours: covariate (input) drift and concept (label) drift. Detection requires real-world performance monitoring with appropriate ground truth and statistical tests.
  AI/ML
  See also RWPPCCP
- ## EU AI Act
  #ai-act
  Regulation (EU) 2024/1689
  EU horizontal regulation on artificial intelligence, in force August 2024 with phased application through 2027.
  Risk-tiered: prohibited practices (Art. 5), high-risk systems (Art. 6 + Annex III), limited-risk transparency obligations (Art. 50), and general-purpose AI models (Chapter V).
  EU AI/ML
  EU AI Act text (https://artificialintelligenceact.eu/the-act/) See also Article 6Annex IIIFRIA
- ## EUDAMED
  #eudamed
  European Database on Medical Devices
  Central EU database for actor, UDI/device, certificate, clinical investigation, vigilance, and market-surveillance data.
  Some modules are mandatory; others are being phased in. UDI registration is required before placing devices on the EU market.
  EU
  See also UDIMDR
- ## FRIA
  #fria
  Fundamental Rights Impact Assessment
  Assessment required by Art. 27 of the AI Act for deployers of certain high-risk AI systems, primarily public bodies.
  Covers process description, period and frequency of use, categories of affected persons, specific risks of harm to fundamental rights, human-oversight measures, and the response plan if risks materialise.
  EU AI/ML
  See also EU AI Act
- ## GMLP
  #gmlp
  Good Machine Learning Practice
  Ten guiding principles jointly published by FDA, Health Canada, and MHRA for the development of ML-enabled medical devices.
  Covers multi-disciplinary expertise, good software engineering, representative datasets, training/test independence, performance evaluation, model selection, transparency, deployment monitoring, and security.
  FDA Canada UK AI/ML
  FDA, GMLP Guiding Principles (https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles) See also PCCPSaMD
- ## Health Canada
  #health-canada
  Health Canada, Therapeutic Products Directorate
  Canadian medical-device regulator. Co-author of the GMLP guiding principles with FDA and MHRA.
  Operates a four-class licensing system. Recognises ISO 13485 via MDSAP. Issued draft pre-market guidance for ML-enabled medical devices in 2023.
  Canada AI/ML
  See also GMLPMDSAP
- ## IEC 62304
  #iec-62304
  IEC 62304, Medical device software lifecycle processes
  International standard for the lifecycle of medical-device software, with safety classes A, B, C based on potential harm.
  Defines processes for software development, maintenance, risk management, configuration management, and problem resolution. Foundational to most software medical-device submissions.
  International Quality
  See also ISO 13485IEC 62366
- ## IEC 62366
  #iec-62366
  IEC 62366-1, Application of usability engineering to medical devices
  International standard for usability engineering and human-factors validation of medical devices.
  Critical for AI devices intended for clinician decision-support, where automation bias and over-reliance are foreseeable use errors.
  International Quality
  See also IEC 62304ISO 14971
- ## IMDRF
  #imdrf
  International Medical Device Regulators Forum
  Voluntary group of medical-device regulators (FDA, EMA, MHRA, Health Canada, NMPA, PMDA, TGA, ANVISA) that publishes harmonised guidance.
  Successor to the Global Harmonization Task Force. IMDRF documents (e.g., the SaMD risk-categorisation framework N12) are non-binding but heavily cited by national regulators.
  International
  IMDRF homepage (https://www.imdrf.org/) See also SaMDIMDRF N12GMLP
- ## IMDRF N12
  #n12
  SaMD: Possible Framework for Risk Categorization
  Risk-categorisation matrix that maps SaMD into Categories I–IV using significance of information × healthcare situation.
  Two axes: significance of information provided (inform / drive / treat or diagnose) and state of healthcare situation (non-serious / serious / critical). Adopted as the conceptual basis for FDA's SaMD framework and informs MDR Rule 11.
  International
  IMDRF/SaMD WG/N12 (2014) (https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-140918-samd-framework-risk-categorization-141013.pdf) See also SaMDMDR Rule 11
- ## ISO 13485
  #iso-13485
  ISO 13485:2016, Medical devices, Quality management systems
  International QMS standard for medical device manufacturers; the reference standard for EU MDR and (from Feb 2026) the FDA QMSR.
  Specifies requirements for a QMS where an organisation needs to demonstrate its ability to provide medical devices that consistently meet customer and applicable regulatory requirements.
  International Quality
  See also QMSRISO 14971IEC 62304
- ## ISO 14971
  #iso-14971
  ISO 14971:2019, Application of risk management to medical devices
  International standard for medical-device risk management across the full product lifecycle.
  Required (or strongly expected) by every major regulator. Defines hazard, harm, risk, risk control, and benefit-risk analysis. AAMI TIR34971 extends the framework to AI/ML devices.
  International Quality AI/ML
  See also ISO 13485IEC 62304TIR 34971
- ## IVDR
  #ivdr
  Regulation (EU) 2017/746, EU In Vitro Diagnostic Regulation
  EU regulation governing in-vitro diagnostic medical devices, including IVD software.
  Companion to the MDR with its own classification rules (Classes A–D). Covers diagnostic algorithms operating on patient samples.
  EU
  See also MDR
- ## MDCG 2019-11
  #mdcg-2019-11
  Guidance on Qualification and Classification of Software (rev.1, June 2025)
  EU Medical Device Coordination Group guidance for deciding whether software is a medical device and how to classify it under MDR/IVDR.
  Endorsed by all EU Member States. Provides decision trees for MDSW qualification and worked examples for Rule 11 classification.
  EU
  See also MDRMDR Rule 11MDSW
- ## MDR
  #mdr
  Regulation (EU) 2017/745, EU Medical Device Regulation
  EU regulation governing medical devices, replacing the MDD. Software medical devices are classified under Rule 11.
  Came into application on 26 May 2021. Mandates Notified Body conformity assessment for Class IIa and above, clinical evaluation, post-market surveillance, and EUDAMED registration.
  EU
  See also MDR Rule 11MDCG 2019-11Notified BodyEUDAMED
- ## MDR Rule 11
  #rule-11
  Annex VIII Rule 11 of the EU MDR
  Classification rule for software intended to provide information used to take decisions for diagnostic or therapeutic purposes, at least Class IIa.
  IIb if decisions may cause serious deterioration or surgical intervention; III if death or irreversible deterioration. Software for monitoring physiological processes is IIa (IIb where variations could result in immediate danger).
  EU
  MDCG 2019-11 rev.1 (https://health.ec.europa.eu/document/download/b45335c5-1679-4c71-a91c-fc7a4d37f12b_en) See also MDRMDCG 2019-11
- ## MDSAP
  #mdsap
  Medical Device Single Audit Program
  Programme allowing a single QMS audit to satisfy regulators in Australia, Brazil, Canada, Japan, and the US.
  Audit reports are accepted by participating regulators in lieu of their own routine inspections. Built on ISO 13485.
  International Quality
  See also ISO 13485QMSR
- ## MDSW
  #mdsw
  Medical Device Software
  Software that meets the MDR/IVDR definition of a medical device, the European counterpart of SaMD.
  MDCG 2019-11 walks through the qualification decision: software is MDSW if it has a medical purpose on its own (not merely storage, communication, or simple search).
  EU
  See also SaMDMDCG 2019-11
- ## MHRA
  #mhra
  Medicines and Healthcare products Regulatory Agency
  UK regulator for medicines and medical devices, including AIaMD.
  Operates the AI Airlock sandbox and is delivering an AIaMD change programme aligned with FDA's GMLP and PCCP work.
  UK AI/ML
  MHRA AIaMD programme (https://www.gov.uk/government/publications/software-and-artificial-intelligence-ai-as-a-medical-device) See also AIaMDGMLP
- ## Model Card
  #model-card
  Structured disclosure document describing an AI model's intended use, training data, performance, limitations, and known biases.
  Originally proposed by Mitchell et al. (2019). Endorsed by FDA's Transparency for ML-Enabled Medical Devices guiding principles as a recommended format.
  AI/ML
  Mitchell et al., Model Cards for Model Reporting (https://arxiv.org/abs/1810.03993) See also Transparency PrinciplesGMLP
- ## NMPA
  #nmpa
  National Medical Products Administration (China)
  China's medical-device regulator. Publishes specific AI/ML medical-device technical guidance.
  Successor to CFDA. AI medical software is classified by intended use and risk; high-risk AI typically requires Class III registration with clinical data from Chinese sites.
  China AI/ML
  See also SaMD
- ## Notified Body
  #notified-body
  Notified Body (EU)
  Independent conformity-assessment organisation designated by an EU Member State to audit MDR/IVDR compliance for Class IIa+ devices.
  Issues CE certificates after auditing the manufacturer's QMS and reviewing technical documentation. Examples: BSI, TÜV SÜD, DEKRA.
  EU
  See also MDRCE Mark
- ## PCCP
  #pccp
  Predetermined Change Control Plan
  An FDA-authorised plan that lets a manufacturer implement specified post-market modifications to an AI device without a new submission.
  Three required components: Description of Modifications, Modification Protocol, and Impact Assessment. Each modification must still meet quality-system requirements (full design-control V&V of the entire device).
  FDA AI/ML
  FDA Final Guidance (Dec 2024, rev. Aug 2025) (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial) See also GMLPSaMDQMSR
- ## PMA
  #pma
  Premarket Approval
  FDA's most stringent pathway, required for Class III devices that support or sustain human life or pose unreasonable risk.
  Requires valid scientific evidence (typically clinical investigation) of safety and effectiveness. Often involves Advisory Committee review for novel AI.
  FDA
  See also 510(k)De Novo
- ## Premarket Cyber
  #premarket-cyber
  FDA Premarket Cybersecurity Guidance (2023)
  FDA guidance on cybersecurity content in premarket submissions, mandated by section 524B of the FD&C Act.
  Requires a Secure Product Development Framework, threat modelling, SBOM, vulnerability management plan, and post-market patching commitments for any cyber device.
  Cybersecurity FDA
  FDA Cybersecurity in Medical Devices guidance (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) See also SBOM
- ## Q-Sub
  #qsub
  Q-Submission Program (Pre-Submission)
  FDA mechanism for soliciting agency feedback before formal marketing submission.
  Highly recommended for novel AI devices, automatic implementation of modifications, or any PCCP element where alignment with FDA review division is uncertain.
  FDA
  See also PCCP510(k)De Novo
- ## QMSR
  #qmsr
  Quality Management System Regulation
  FDA's successor to 21 CFR 820, incorporating ISO 13485:2016 by reference. Effective 2 February 2026.
  Aligns FDA's quality-system requirements with the global ISO 13485 baseline used by the EU MDR, MDSAP, and most other major jurisdictions, reducing duplicate compliance burden.
  FDA Quality
  Federal Register notice (https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments) See also QSRISO 13485MDSAP
- ## QSR
  #qsr
  Quality System Regulation (21 CFR Part 820)
  FDA's medical-device quality-system rule. Replaced by the QMSR effective 2 February 2026.
  Sets requirements for design controls, document controls, CAPA, complaint handling, and other QMS elements for device manufacturers selling in the US.
  FDA Quality
  See also QMSRISO 13485
- ## RWP
  #rwp
  Real-World Performance
  Ongoing measurement of an AI device's performance after deployment, on real clinical data.
  Distinct from real-world evidence (RWE), RWP focuses on monitoring for drift, subgroup degradation, and unexpected failure modes. Often required as part of a PCCP monitoring plan.
  AI/ML Clinical
  See also PCCPDrift
- ## SaMD
  #samd
  Software as a Medical Device
  Software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device.
  Defined by the IMDRF in N10 and N12. Distinguishes pure-software medical devices from Software in a Medical Device (SiMD), software embedded in hardware. Most AI-enabled medical products today fall under SaMD.
  International AI/ML
  IMDRF SaMD WG/N10 (https://www.imdrf.org/documents/software-medical-device-samd-key-definitions) See also SiMDIMDRFIMDRF N12
- ## SBOM
  #sbom
  Software Bill of Materials
  Machine-readable inventory of software components, used to assess vulnerability exposure.
  Required by FDA's 2023 premarket cybersecurity guidance for cyber devices. Common formats: SPDX and CycloneDX.
  Cybersecurity FDA
  See also Premarket Cyber
- ## SiMD
  #simd
  Software in a Medical Device
  Software embedded inside a hardware medical device, distinct from SaMD.
  Examples include firmware in an infusion pump or the controller of a CT scanner. SiMD is regulated as part of the parent device, not as a standalone software device.
  International
  See also SaMD
- ## TIR 34971
  #tir34971
  AAMI TIR34971, Application of ISO 14971 to AI/ML
  AAMI Technical Information Report applying ISO 14971 risk management to AI- and ML-enabled medical devices.
  Provides AI-specific hazards (e.g., dataset shift, automation bias, adversarial inputs) and recommended controls. Increasingly cited in FDA submissions and Notified Body reviews.
  AI/ML Quality
  See also ISO 14971GMLP
- ## Transparency Principles
  #transparency
  Transparency for ML-Enabled Medical Devices
  FDA / Health Canada / MHRA guiding principles on what information should be disclosed to users of AI-enabled devices.
  Companion to the GMLP principles. Covers what, why, where, and how information should be communicated, including model purpose, training data, performance, and limitations.
  FDA UK Canada AI/ML
  FDA Transparency Principles (https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles) See also Model CardGMLP
- ## UDI
  #udi
  Unique Device Identifier
  Globally unique identifier required by FDA, EU MDR, and other major jurisdictions for traceability and post-market surveillance.
  FDA PCCP guidance requires a new UDI for new versions/models and for new device packages, including model updates implemented under an authorised PCCP.
  FDA EU International
  See also PCCPEUDAMED

© 2026 AI SaMD Playbook · Sponsored by Blue Goat Cyber

Editorial reference only. Not legal or regulatory advice.

## Structured data

```json
[
  {
    "@context": "https://schema.org",
    "@graph": [
      {
        "@type": "WebSite",
        "@id": "https://ai-samd.com/#website",
        "url": "https://ai-samd.com/",
        "name": "AI SaMD Playbook",
        "description": "Working reference for regulating AI/ML Software as a Medical Device: FDA, EU AI Act, MHRA, Health Canada and NMPA guidance, model risks, and cybersecurity for RA/QA teams.",
        "inLanguage": "en"
      },
      {
        "@type": "Organization",
        "name": "Blue Goat Cyber",
        "url": "https://bluegoatcyber.com"
      }
    ]
  },
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://ai-samd.lovable.app/"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Glossary",
        "item": "https://ai-samd.lovable.app/glossary"
      }
    ]
  }
]
```